SPOTLIGHT: UK renegotiating drug prices


The U.K.'s new health minister is threatening to jettison the government's current pricing deal with drug makers--and you can bet it's not planning to pay more for the meds doled out by the National Health Service. Report

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.